In August, the FDA approved Addyi, the first drug authorized to treat hypoactive sexual desire disorder (HSDD), or lack of libido. As the first such pharmaceutical designed for women, the press dubbed it Female Viagra — incorrectly, since Viagra and its cohort address the physical issue of erectile dysfunction and are taken as needed. Addyi, or flibanserin, tweaks the brain’s mix of neurotransmitters dopamine and serotonin, must be taken daily and can take two months to fully kick in.
Unfortunately, the results are, um, anticlimactic. Relative to the placebo, only an additional 10 percent of women in trials had a marked response: hardly one more sexually satisfying event per month. “Not very many, in light of all of the significant side effects,” worries Lori Brotto, a University of British Columbia…
